This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1192/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q72659567
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel im Oktober 1993 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в жовтні 1993 artículu científicu espublizáu n'ochobre de 1993 scientific article published on 01 October 1993
p:P577
wds:Q72659567-89596B24-1A89-4E45-969D-9E6B9FE60796
wdt:P577
1993-10-01T00:00:00Z
p:P2860
wds:Q72659567-FE1603EB-522E-4E8B-B9A5-D8FDF24739D5
wdt:P2860
wd:Q34280408
p:P2093
wds:Q72659567-5A792BAA-936E-434D-B3DB-E716F77F1EFD wds:Q72659567-407AC997-FD94-4A5D-9C8D-630ACD6F4815 wds:Q72659567-E4EB1D9B-B119-446F-9535-707893D6EEA6 wds:Q72659567-AE7262FC-751D-4F3C-80D9-5F48CE597C9A wds:Q72659567-B34758DB-C5EE-4D60-BD5F-51209C5A36D3 wds:Q72659567-F40DA558-802A-4B9B-8E83-4929C4F92C0A wds:Q72659567-781154FE-47E6-4FF2-B0E3-F12C2F99F716 wds:Q72659567-85E3D4CE-CFED-4092-81B4-7BA1C6E5311E
wdt:P2093
S J Duinkerke H L Busard A J van Haaften J H van Laarhoven P A van Dongen A A Jansen P A Botter A J Boom
rdfs:label
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
skos:prefLabel
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
schema:name
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
p:P1476
wds:Q72659567-F0299E11-39B9-4579-9B27-5C31ED6D635C
wdt:P1476
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
p:P304
wds:Q72659567-5C948BDF-54D8-45F1-A590-006C1949CD8C
wdt:P304
451-455
p:P31
wds:Q72659567-D70A83D0-2D77-465D-B846-379CB86F1118
wdt:P31
wd:Q13442814
p:P921
wds:Q72659567-C9C38CF8-FECF-41BF-92CB-5F02C31D1BA4 wds:Q72659567-9EA5E41F-C03A-468C-98E2-4B153950F72D
wdt:P921
wd:Q269829 wd:Q41112
p:P698
wds:Q72659567-4D0B32A5-6813-4C0B-96EB-499525BE501C
wdtn:P698
n7:7902766
wdt:P698
7902766
p:P1433
wds:Q72659567-2EB59D72-12AC-4C83-AC7E-DAA5B51DCED8
wdt:P1433
wd:Q4035428
p:P478
wds:Q72659567-208A7EA5-8F30-4CD7-B017-BD3B8259977A
wdt:P478
163
p:P356
wds:Q72659567-0C83EFD4-8D80-4FFA-8B21-582B601E8588
wdtn:P356
n10:BJP.163.4.451
wdt:P356
10.1192/BJP.163.4.451